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matched samples of employees with osteoarthritis (OA) and non-
FM controls. METHODS: Samples were selected from a U.S.
claims database of privately insured beneﬁciaries. Employees in
the FM sample had ≥2 ﬁbromyalgia diagnoses in 1999–2005
(with ≥1 in 2002–2005) and were continuously enrolled in 2005.
Controls and employees with OA had no FM claims and were
matched to the study sample on age, gender, and region. Costs
are reported for 2005 experience. Nonparametric Wilcoxon tests
were used to determine statistically signiﬁcant differences in
skewed variables including costs. Chi-square tests were used to
test for differences in for categorical variables. RESULTS: Mean
age in the FM sample was 50.1 years and 51.6% were female.
Compared to control and OA samples, employees with FM had
higher rates of depression, anxiety, chronic fatigue syndrome,
and many pain diagnoses. The FM sample used more medical
care overall, especially emergency department visits, specialty
physician visits, and prescriptions. Direct (medical and prescrip-
tion drug) costs in the FM sample were signiﬁcantly higher 
than control sample costs ($7286 vs. $3915, p < 0.0001), and
approached OA sample costs ($7286 vs. $8325, p = 0.3758).
Prescription costs comprised a relatively large proportion of total
FM costs; prescription cost levels were comparable to employ-
ees with OA ($1630 vs. $1341, p < 0.3541) and signiﬁcantly
higher than controls ($1630 vs. $755, p < 0.0001). Work loss
costs in the FM sample ($2913) were signiﬁcantly higher than
those of control ($1359, p < 0.0001) and OA ($2537, p <
0.0001) samples. CONCLUSIONS: Fibromyalgia imposes sig-
niﬁcant economic burden. Average total costs among employees
with ﬁbromyalgia were almost twice those of matched controls
and approximated costs of employees with osteoarthritis. Indi-
rect costs were more than double those of controls and even
exceeded costs of osteoarthritis patients with similar demo-
graphic proﬁles.
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OBJECTIVES: Patients with insomnia are likely to have comor-
bidities that could affect treatment options. Hence the objective
of this study was to examine the prevalence of comorbidities and
their impact on the pharmacological treatment of insomnia in
US primary care settings. METHODS: A retrospective data
analysis of the National Ambulatory Medical Care Survey from
1995 to 2004 was performed. Patients aged ≥18 years, who had
a physician visit with a diagnosis of insomnia in US outpatient
settings were included in this study. Ofﬁce visits of patients with
primary or secondary insomnia/sleep complaints and resultant
diagnoses were included in the analysis. Data were stratiﬁed
according to patient characteristics, physician specialty, resulting
diagnosis and medications prescribed. Multivariate logistic
regression models were used to examine impact on prescribing
pharmacotherapy for insomnia. RESULTS: A total of 5487
unweighted patient visits for insomnia were identiﬁed from the
year 1995–2004, representing 107.4 million patients in the
overall U.S. population. Ofﬁcial visits for insomnia were more
common in females (60.4%), with an increasing prevalence in
older patients. Approximately 41% of the patients with insom-
nia had a concomitant diagnosis of a mental comorbidity with
higher prevalence of anxiety (15.6%) followed by episodic mood
disorders (14.9%) and depression (7%). Patients with mental
comorbidities were 35% less likely to receive pharmacological
treatment for insomnia than those without mental comorbidities
(OR: 0.65, 95% CI: 0.51–0.84). Subgroup analysis of type of
mental comorbidity revealed that patients with comorbid anxiety
were 42% less likely to receive pharmacological treatment for
insomnia than those without anxiety (OR: 0.58, 95% CI:
0.45–0.73). CONCLUSION: Mental comorbidities such as
episodic mood disorder, anxiety, and depression are prevalent in
patients with insomnia and affect receipt of pharmacological
therapy for insomnia. Health care professionals should consider
the impact of mental comorbidities while treating patients with
sleep difﬁculties.
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OBJECTIVES: The objective of this study is to quantify the
strength of preferences of older Americans for possible
Alzheimer’s disease (AD) treatment beneﬁts by estimating their
willingness to accept the risk of death or severe disability in
exchange for modifying the course of AD. Currently, AD has no
cure. A breakthrough in treatment that modiﬁes the underlying
AD disease process would be a major achievement with enor-
mous medical and social beneﬁts. Little is known concerning
older Americans’ perceptions about AD and their willingness to
accept risk to avoid AD. METHODS: American residents aged
60 years and older who have not been diagnosed with AD, and
are not taking prescription medicines to treat AD, memory prob-
lems or dementia completed an online survey questionnaire that
included a series of stated-choice trade-off tasks. Respondents
chose between pairs of hypothetical treatment alternatives, each
including different 7-year AD disease-progression proﬁles and
risks of serious adverse events that would result in death or
severe disability. We used mixed-logit methods to estimate the
maximum acceptable risk (MAR) of serious adverse events that
would result in death or severe disability. RESULTS: 2146
respondents completed the survey. Mean (SD) age was 70 (7.4).
In return for preventing AD from progressing beyond the mild
stage, the mean MAR (95% CI) was 46.8% (40.3%–54.3%);
that is older Americans were willing, on average, to accept an
increase in the risk of death or severe disability from stroke of
nearly 50% to avoid progression to the moderate and severe
stages of AD. CONCLUSION: Older Americans’ willingness to
accept signiﬁcant increases in the risk of death or disability in
exchange for treatments that modify the course of AD indicates
the value of such treatment beneﬁts.
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OBJECTIVES: To assess the cost-effectiveness of using a lido-
caine 5% medicated plaster (lidocaine plaster) in the treatment
of post-herpetic neuralgia (PHN) in place of gabapentin from the
perspective of the Scottish National Health Service. METHODS:
A Markov model was constructed in TreeAge to calculate the
costs and beneﬁts of gabapentin and lidocaine plaster when used
in primary care over a six-month time horizon in patients with
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PHN who have insufﬁcient pain relief with standard analgesics
and do not tolerate or are contraindicated to tricyclic antide-
pressants. The model structure allowed for differences in costs,
utilities and transition probabilities between the initial 30-day
run-in period and maintenance therapy and also took account of
other medications that are added in alongside gabapentin/lido-
caine plaster and those received by patients discontinuing
gabapentin/lidocaine plaster. Most transition probabilities were
based on clinical trials identiﬁed through a systematic literature
review. Missing data, including resource utilization, were
obtained from a Delphi panel and cost data from ofﬁcial price
lists and tariffs. Utilities derived from a published study using
the Health Utilities Index were adjusted for age and were sup-
plemented and validated by the Delphi panel. RESULTS: The
total cost for lidocaine plaster was £958 per patient, compared
with £789 for gabapentin, although lidocaine plaster generated
0.292 quality-adjusted life-years (QALYs), compared with 0.248
for gabapentin. Lidocaine plaster therefore cost £3767 ($7370;
95% conﬁdence interval: dominant, £13,415) per QALY gained
relative to gabapentin. Probabilistic sensitivity analysis demon-
strated that we can be 98.7% conﬁdent that lidocaine plaster is
cost-effective relative to gabapentin at a £20,000/QALY thresh-
old and 65% conﬁdent at a £5000/QALY threshold. Scenario
analyses and extensive one-way sensitivity analyses on all para-
meters including the time horizon conﬁrmed the robustness of
the results. CONCLUSION: The lidocaine 5% plaster is a highly
cost-effective treatment for PHN in Scotland.
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OBJECTIVES: QuantiFERON-TB Gold assay (QFT-G) is a
recently approved blood test for detection of tuberculosis (TB)
infection. The advantages of tuberculin skin test (TST) are;
improved speciﬁcity, unaffected by prior BCG vaccination, and
single patient visit. The aim of this study was to examine the cost
effectiveness of using QFT-G as a screening test followed by the
standard treatment of TB infected patients after exposure in close
contacts in Japan. METHODS: We used a Markov model to
compare the cost and effectiveness of QFT-G alone, TST alone,
and TST followed by QFT-G using a hypothetical adult cohort
(20 years old) of close contact patients with sputum-smear-
positive TB patients. Main outcome measure was incremental
cost per Quality adjusted life year (QALY) gained during life-
time. In the model, costs and effectiveness of each screening test,
further chest X-ray examination, prophylaxis after identifying as
infected patients, and treatment for overt tuberculosis patients
who is not identiﬁed by screening or suffer from the disease even
after prophylaxis were considered and estimated with published
literatures. Both deterministic one-way and probabilistic sensi-
tivity analysis were performed. RESULTS: TST alone was the
most expensive and the least effective alternative. The mean
QALYs for QFT-G only strategy was slightly higher than that for
TST followed by QFT-G strategy (27.0565 vs. 27.0564). Total
costs from the societal perspective were higher on average for
the TST followed by QFT-G strategy ($120.9) than the QFT-G
alone strategy ($112.9). The incremental cost effectiveness ratio
for QFT-G alone strategy dominated. The results were robust in
deterministic one-way sensitivity analysis while the acceptability
curve showed that the QFT-G alone strategy has 99.6% chance
of being cost effective at $50,000/QALY gained threshold. CON-
CLUSION: QFT-G alone strategy is the least expensive and the
most effective in screening the TB infection after exposure in
close contacts in Japan.
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OBJECTIVES: The purpose of this study was to estimate the
total and incremental costs associated with antibiotic treatments
for community acquired pneumonia (CAP). METHODS:
Persons over age 18 were identiﬁed in the Marketscan databases
July-December 2004. We identiﬁed CAP episodes for patients
with claims for ICD9 codes 481.XX–486.XX, plus the most fre-
quent antibiotics prescribed as initial treatment for an episode.
Logistic regression estimated a propensity score for each patient;
which was the predicted probability of using telithromycin.
Patients were then matched according to this probability. Then
exponential conditional means models (ECM) were speciﬁed,
controlling for variables that were still signiﬁcantly different
after the propensity score matching. These models allowed the
incremental costs to be estimated for treatment of telithromycin
relative to other antibiotics. RESULTS: The most common ini-
tial antibiotic treatments compared to telithromycin for CAP 
(n = 187 CAP episodes) were amoxicillin, azithromycin, clar-
ithromycin, levoﬂoxacin, moxiﬂoxacin, and a group of all other
antibiotics. The mean length of a CAP episode was from 11.5 to
16.5 days. Mean total expenditures among the episodes was
$897, with a range of $530 to $1175. Multivariate ECM models
were ﬁtted and showed signiﬁcant incremental cost reductions
per episode associated with telithromycin relative to: amoxicillin
(−$283, p = 0.002), azithromycin (−$686, p < 0.001), lev-
oﬂoxacin (−$411, p < 0.001), and moxiﬂoxacin (−$484, p <
0.001). The difference between telithromycin and clarithromycin
(−$52) was not signiﬁcant. CONCLUSION: The results of this
study show that the costs differed among episodes of CAP by the
initiating antibiotic. Use of propensity score matching and ECM
regression controlled for intra-episode differences, so the incre-
mental costs differences may be attributed to factors such as
length of episode. The costs of CAP can be substantial and it is
important to note that the initiating antibiotic may affect those
costs.
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OBJECTIVES: With increasing longevity among the elderly, it is
important to better understand the impact of chronic disease on
general health status. The objective of this study was to quan-
tify the health status burden of COPD for a nationally repre-
